Evaxion Biotech reaches a key milestone in melanoma research as all patients complete dosing in its AI-driven personalized …
Evaxion Biotech reaches a key milestone in melanoma research as all patients complete dosing in its AI-driven personalized …
ViGeneron’s VG901 gains momentum with FDA rare pediatric disease status for CNGA1‑linked retinitis pigmentosa, while the EMA urges …
With a PDUFA date set for June 2025, the copper histidinate therapy may soon become the first FDA-approved …
A novel collaboration breaks ground with an inhaled mRNA therapy entering early clinical testing for the first time—a …
Neumora Therapeutics sees its share value collapse as its lead antidepressant candidate, navacaprant, fails to outperform placebo in …
As 2024 wraps up, end-of-year research highlights—from AI-driven disease detection to expanded diagnoses and novel trial milestones—are shaping …
As 2024 concludes, insights from Velocity Clinical Research highlight how clinical trial operations next year will be shaped …
Humacyte’s Symvess offers a novel solution for patients with severe vascular injuries, marking a significant advancement in trauma …
December marks a turning point in computational biology, with Exscientia’s AI-designed oncology candidate advancing to mid-stage trials—reshaping how …
On December 19, the clinical research world turns its attention to psychedelic medicine, with new data, global trial …
Already a subscriber? Log in